J. Peña

发表

HLA-B18 as a risk factor of short-term progression to severe liver fibrosis in HIV/HCV co-infected patients with absent or minimal fibrosis: implications for timing of therapy

J. Torre-Cisneros, M. Frias, D. Rodriguez-Cano, 2016, The Pharmacogenomics Journal.

Decline and Changing Profile of Hepatitis Delta among Injection Drug users in Spain

V. Soriano, A. Aguilera, J. Peña, 2018, Antiviral therapy.

Delta hepatitis: new approaches to therapy

V. Soriano, J. Peña, P. Labarga, 2016 .

New hepatitis C therapies for special patient populations

V. Soriano, I. Esposito, J. Peña, 2016, Expert opinion on pharmacotherapy.

Emerging Challenges in Managing Hepatitis B in HIV Patients

V. Soriano, I. Esposito, J. Peña, 2015, Current HIV/AIDS Reports.

Dual antiviral therapy for HIV and hepatitis C – drug interactions and side effects

V. Soriano, I. Esposito, J. Peña, 2015, Expert opinion on drug safety.

Surgery as an Adjunctive Treatment for Multidrug-Resistant Tuberculosis: An Individual Patient Data Metaanalysis.

Sonya S. Shin, T. Holtz, J. Yim, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

A randomized trial comparing the efficacy and tolerability of two HAART strategies at two years in antiretroviral naive patients.

J. Miro, J. Gatell, J. Mallolas, 2007, Revista clinica espanola.

Drug interactions in HIV-infected patients treated for hepatitis C

V. Soriano, J. Peña, P. Labarga, 2017, Expert opinion on drug metabolism & toxicology.

Treatment of hepatitis C with new fixed dose combinations

V. Soriano, J. Peña, C. de Mendoza, 2017, Expert opinion on pharmacotherapy.

Evaluation of sofosbuvir, velpatasvir plus voxilaprevir as fixed-dose co-formulation for treating hepatitis C

V. Soriano, J. Peña, C. de Mendoza, 2017, Expert opinion on drug metabolism & toxicology.

Abnormalities in the bone mineral metabolism in HIV-infected patients

S. Muñoz Fernández, J. Arribas, J. Peña, 2006, Clinical Rheumatology.

Drug interactions with new hepatitis C oral drugs

V. Soriano, I. Esposito, J. Peña, 2015, Expert opinion on drug metabolism & toxicology.

Soluble HLA-G in heart transplantation: their relationship to rejection episodes and immunosuppressive therapy.

J. Peña, D. Pascual, M. Álvarez-López, 2006, Human immunology.

sHLA-G levels in the monitoring of immunosuppressive therapy and rejection following heart transplantation.

J. Lozano, J. Peña, M. Álvarez-López, 2006, Transplant immunology.

Effects on innate immunity of a therapeutic dendritic cell-based vaccine for HIV-1 infection.

Felipe García, M. Plana, T. Gallart, 2012, Viral immunology.

New advances in coeliac disease: serum and intestinal expression of HLA-G.

J. Peña, María Inés Torres, M. López-Casado, 2006, International immunology.

Natural Killer KIR3DS1 Is Closely Associated with HCV Viral Clearance and Sustained Virological Response in HIV/HCV Patients

J. Torre-Cisneros, B. Manzanares-Martín, J. Pineda, 2013, PloS one.

CD8(+)HLA-G(+) regulatory T cells are expanded in HIV-1-infected patients.

J. Lozano, M. Frias, J. Peña, 2009, Viral immunology.

Clinical, Virologic, and Immunologic Response to Efavirenz-or Protease Inhibitor–Based Highly Active Antiretroviral Therapy in a Cohort of Antiretroviral-Naive Patients With Advanced HIV Infection (EfaVIP 2 Study)

J. Gatell, J. Arribas, J. Peña, 2004, Journal of acquired immune deficiency syndromes.

Effects of Hepatitis C Virus (HCV) Eradication on Bone Mineral Density in Human Immunodeficiency Virus/HCV-Coinfected Patients

M. Salavert, J. Navarro, A. Curran, 2020, Clinical Infectious Diseases.

Rate and Predictors of Treatment Failure to All-Oral HCV Regimens outside Clinical Trials

V. Cuervas-Mons, V. Soriano, A. Aguilera, 2016, Antiviral therapy.

High Serum HCV RNA in Chronic Hepatitis C Patients Coinfected with HIV despite Successful Antiretroviral Therapy

V. Soriano, J. Peña, C. de Mendoza, 2016, Antiviral therapy.

KIR2DS2 as predictor of thrombocytopenia secondary to pegylated interferon-alpha therapy

M. Frias, D. Rodriguez-Cano, A. Gordon, 2016, The Pharmacogenomics Journal.

Advances in treating drug-resistant hepatitis B virus in HIV-infected patients

V. Soriano, J. Peña, C. de Mendoza, 2015, Expert opinion on pharmacotherapy.

Lopinavir/Ritonavir as Single-Drug Therapy for Maintenance of HIV-1 Viral Suppression: 48-Week Results of a Randomized, Controlled, Open-Label, Proof-of-Concept Pilot Clinical Trial (OK Study)

A. Carcas, F. Gayá, J. Arribas, 2005, Journal of acquired immune deficiency syndromes.

Impact of protease inhibitor therapy on HIV-related oropharyngeal candidiasis

W. Powderly, J. Arribas, J. Peña, 2000, AIDS.

Discontinuation of primary and secondary Toxoplasma gondii prophylaxis is safe in HIV-infected patients after immunological restoration with highly active antiretroviral therapy: results of an open, randomized, multicenter clinical trial.

D. Podzamczer, J. Miro, E. Martinez, 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

14-Base pair polymorphism of human leukocyte antigen-G as genetic determinant in heart transplantation and cyclosporine therapy monitoring.

J. Peña, P. Lorite, T. Palomeque, 2009, Human immunology.

New antivirals for the treatment of chronic hepatitis B

V. Soriano, J. Peña, C. de Mendoza, 2017, Expert opinion on investigational drugs.

Interferon plus ribavirin in HIV-infected patients with chronic hepatitis C.

V. Soriano, J. Arribas, M. Pérez-Olmeda, 1999, Journal of acquired immune deficiency syndromes.

Prevention and management of treatment failure to new oral hepatitis C drugs

V. Soriano, J. Peña, C. de Mendoza, 2016, Expert opinion on pharmacotherapy.

Rate and predictors of serum HCV-RNA >6 million IU/mL in patients with chronic hepatitis C.

V. Soriano, J. Peña, P. Labarga, 2015, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Incidence of Liver Damage of Uncertain Origin in HIV Patients Not Co-Infected with HCV/HBV

J. Torre-Cisneros, J. Macías, J. Pineda, 2013, PloS one.

Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR

I. Martínez, M. Salavert, E. Ribera, 2019, Scientific Reports.

Hepatic Decompensation with Sofosbuvir plus Simeprevir in a Patient with Child–Pugh B Compensated Cirrhosis

V. Soriano, J. Peña, C. de Mendoza, 2016, Antiviral therapy.

Treatment outcomes of patients with multidrug-resistant and extensively drug-resistant tuberculosis according to drug susceptibility testing to first- and second-line drugs: an individual patient data meta-analysis.

M. L. van der Walt, V. Leimane, M. Narita, 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

University of Groningen Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes

Wiel, Sonya S. Shin, T. Holtz, 2012 .

Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1.

B. Clotet, J. Martinez-Picado, C. Brander, 2015, The Journal of antimicrobial chemotherapy.

Emerging topics and new perspectives on HLA-G

M. Stignani, O. Baricordi, E. Fainardi, 2011, Cellular and Molecular Life Sciences.

Monocytes and T lymphocytes in HIV-1-positive patients express HLA-G molecule

J. Dausset, N. Rouas-Freiss, E. Carosella, 2002, AIDS.

Dual antiretroviral therapy for HIV infection

V. Soriano, J. Peña, A. Arias, 2017, Expert opinion on drug safety.

High effectiveness of efavirenz-based highly active antiretroviral therapy in HIV-1-infected patients with fewer than 100 CD4 cells/microl and opportunistic diseases: the EfaVIP Study (Efavirenz in Very Immunosuppressed Patients).

J. Gatell, J. Arribas, J. Peña, 2002, AIDS.

Impact of tuberculosis on the course of HIV-infected patients with a high initial CD4 lymphocyte count.

E. Pérez-Rodríguez, J. Peña, F. Pulido, 2004, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

Short Communication: Natural killer cells and expression of KIR receptors in chronic HIV type 1-infected patients after different strategies of structured therapy interruption.

Felipe García, G. Mestre, M. Plana, 2008, AIDS research and human retroviruses.

Treatment of tuberculosis in HIV-infected patients: safety and antiretroviral efficacy of the concomitant use of ritonavir and rifampin.

D. Podzamczer, J. Peña, S. Moreno, 2001, AIDS.

Lipid disorders in antiretroviral-naive patients treated with lopinavir/ritonavir-based HAART: frequency, characterization and risk factors.

J. Arribas, J. Peña, E. Navas, 2005, The Journal of antimicrobial chemotherapy.

HAART induces the expression of HLA-G on peripheral monocytes in HIV-1 infected individuals.

J. Lozano, R. Solana, J. Torre-Cisneros, 2003, Human immunology.

Persistence of Pathological Distribution of NK Cells in HIV-Infected Patients with Prolonged Use of HAART and a Sustained Immune Response

J. Torre-Cisneros, F. Cuenca-López, A. Gordon, 2015, PloS one.

NK-associated regulatory receptors in a structured HAART interruption of HIV-1-positive individuals.

M. Leal, J. Lozano, J. Peña, 2008, AIDS research and human retroviruses.

Correction: Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 Patients

T. Holtz, J. Yim, T. Shim, 2012, PLoS Medicine.

LDLr genotype modifies the impact of IL28B on HCV viral kinetics after the first weeks of treatment with PEG-IFN/RBV in HIV/HCV patients

J. Torre-Cisneros, J. Pineda, Á. Camacho, 2012, AIDS.

Monocytes Phenotype and Cytokine Production in Human Immunodeficiency Virus-1 Infected Patients Receiving a Modified Vaccinia Ankara-Based HIV-1 Vaccine: Relationship to CD300 Molecules Expression

Felipe García, M. Plana, F. Borrego, 2017, Front. Immunol..

A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98.

D. Podzamczer, J. Miro, E. Martinez, 2001, The New England journal of medicine.

Relapse of tuberculosis after treatment in human immunodeficiency virus-infected patients.

J. Peña, F. Pulido, C. Guijarro, 1997, Archives of internal medicine.

Nucleoside reverse transcriptase inhibitors are able and protease inhibitors unable to induce the tolerogenic molecule HLA-G1 on monocytes from HIV-1 infected patients.

J. Lozano, Á. Camacho, J. Peña, 2007, Human immunology.

Treatment outcomes of patients with multidrug-resistant and extensively drug-resistant tuberculosis according to drug susceptibility testing to first- and second-line drugs

M. L. van der Walt, V. Leimane, M. Narita, 2014 .

Low Rate of Adverse Hepatic Events Associated with Fosamprenavir/Ritonavir-Based Antiretroviral Regimens

J. Pineda, J. Peña, M. Pérez-Elías, 2008, HIV Clinical Trials.

New antivirals for the treatment of chronic hepatitis B

V. Soriano, J. Peña, C. de Mendoza, 2017, Expert opinion on investigational drugs.

A New HIV Paradigm: Dual Antiretroviral Regimens as Maintenance Therapy.

V. Soriano, J. Peña, 2017, AIDS reviews.

New advances in coeliac disease: serum and intestinal expression of HLA-G.

J. Peña, María Inés Torres, M. López-Casado, 2006, International immunology.

Therapeutic immunization with an inactivated HIV-1 Immunogen plus antiretrovirals versus antiretroviral therapy alone in asymptomatic HIV-infected subjects.

D. Podzamczer, B. Clotet, G. Sirera, 2004, Vaccine.